ISTH 2023 | Insights into the mechanism of action of fitusiran & the value of this agent in hemophilia treatment
Margaret Ragni, MD, MPH, University of Pittsburgh, Pittsburgh, PA, discusses the mechanism of action of fitusiran, and further discusses the value of this agent in the treatment of patients with both hemophilia A and B. Prof. Ragni also explains how fitusiran may benefit women with heavy menstrual bleeding and bleeding disorders, providing a valuable option for this underserved population. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting and research grants – BioMarin, Sanofi, Spark, Takeda; consulting for BeBio Inc. and for HEMAB, ICER; Serve on Advisory Bd FWGBD; Serve on Editorial Bd for Blood Advances.
